Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of CTP-692 in healthy volunteers
NCT03830463Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing CTP-692 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety at 48 hours, Measurement of CTP-692 exposure in plasma under fasted conditions at 48 hours and 1 more. Started Jan 2019; status: completed.
02
Drugs
deutarserine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03830463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830463.